Premium
Oral eplerenone as a first line treatment in chronic central serous chorioretinopathy: A case series evaluation
Author(s) -
Sendon D.,
Graber M.,
Chiche A.,
Rambaud C.,
Berguiga M.,
Delbarre M.,
FroussartMaille F.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0629
Subject(s) - eplerenone , medicine , visual acuity , ophthalmology , serous fluid , spironolactone , aldosterone
Purpose To evaluate the effect of oral eplerenone on subretinal fluid ( SRF ), visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy ( CSCR ). Methods Retrospective review of all patients monitored for a minimum of 3 months with chronic CSCR lasting more than 3 months who were treated with oral eplerenone with four physicians retina practice. Visual acuity, dilated funduscopic examination, and spectral‐domain ocular coherence tomography ( SD ‐ OCT ) with enhanced depth imaging ( EDI ) were obtained at each visit. The primary outcome measure was the reduction in subretinal fluid ( SRF ) following initiation of therapy. Protocol was oral eplerenone 25 mg daily first week and 50 mg daily during 9 weeks. Results 4 eyes of 4 patients were treated. At 3 months, all eyes had decreased SRF height on OCT and all eyes had improved their visual acuity. Mean SRF height decreased from 390 µm to 285 µm and mean visual acuity enhanced from log MAR 0.20 to 0.08 No significant side effect occurred. Only one eye showed reccurence after eplerenone was discontinued. Conclusions Oral eplerenone appeared to be a safe and reliable treatment with significant anatomic and visual improvements in eyes with chronic CSCR .